TransCode Therapeutics (RNAZ) announced that it has received notice from The Nasdaq Stock Market that the Nasdaq Hearings Panel before which TransCode appeared on October 1, 2024, has determined to grant TransCode’s request to continue its listing on The Nasdaq Stock Market subject to certain conditions to regain compliance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAZ: